---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-106924"
form_type: "8-K"
ticker: "MREO"
cik: "0001719714"
company_name: "Mereo BioPharma Group plc"
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:41:18.960610+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Mereo BioPharma Q2 net loss $14.6M; setrusumab Phase 3 data due year-end 2025

## Summary
- Net loss of $14.6M in Q2 2025 vs $12.3M in Q2 2024; cash $56.1M as of June 30, 2025.
- Phase 3 Orbit and Cosmic studies of setrusumab in OI on track for final analysis around year-end 2025.
- DMC interim analysis in July 2025 confirmed acceptable safety for setrusumab; study continues to final analysis.
- R&D expenses $5.4M (+$0.4M YoY) driven by setrusumab manufacturing; G&A down $2.4M to $5.5M.
- Alvelestat partnering discussions ongoing; cash expected to fund operations into 2027.

## SEC filing metadata
- accession: 0000950170-25-106924
- form_type: 8-K
- ticker: MREO
- cik: 0001719714
- company_name: Mereo BioPharma Group plc
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719714/000095017025106924/0000950170-25-106924-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719714/000095017025106924/mreo-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-106924
- JSON: https://secwatch.observer/filing/0000950170-25-106924.json
- Plain text: https://secwatch.observer/filing/0000950170-25-106924.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.